• Certified Functional Medicine Therapy Provider by AABB
• Hospital Privileges, St. Luke’s Hospital
• MD, Chengdu University of Traditional Chinese Medicine, Sichuan Province, China
• Diplomate, American Academy of Pain Management
• Diplomate in Oriental Medicine, Board Certification
• Associate Professor, American College of Acupuncture
• Provincial Outstanding Physician Award, China, ‘96
• 6th Generation Disciple of Taichi & Qigong
• Speaker, Rice University, Park Plaza, Methodist, St. Luke’s, Memorial Hermann -Hospitals and MD Anderson
• Medical Advisory Board Member, Susan G. Komen Breast Cancer Foundation

weMED Regenerative Medicine is pleased to offer the cutting-edge product Signature Cord, from Signature Biologics.  Signature Biologics is an industry leading research and production laboratory, developed by its founder and chief scientist, Neil Riordan, PA, Ph.D.  The company aspires to leverage Dr. Riordan’s innovative research and manufacturing techniques to produce best-in-class human placental tissue-derived products that will significantly improve and support the body’s natural healing processes and improve patients’ quality of life.

 Signature Cord a natural source of growth factors and hyaluronic acid. Most importantly, it’s processing in the US does not alter the innate properties of the umbilical cord tissue and maintains the source material integrity.

For more information about Signature Biologics, Dr. Riordan and Riordan Technologies, please visit https://www.neilriordan.com/about/

Neil Riordan, PA, Ph.D. is one of the early pioneers and experts in applied Regenerative Medicine research. Dr. Riordan founded publicly traded company Medistem Laboratories (later Medistem Inc.) which was acquired by Intrexon in 2013.

He is the founder and chairman of Medistem Panama, Inc., a leading Regenerative Medicine laboratory and research facility located in the Technology Park of the prestigious City of Knowledge in Panama City, Panama. Medistem Panama (est. 2007) is at the forefront of research on the effects of adult Regenerative Medicines on the course of several chronic diseases and conditions. The Regenerative Medicine laboratory at Medistem Panama is fully licensed by the Ministry of Health of Panama.

Dr. Riordan is the founder, chairman, and chief science officer of the Stem Cell Institute in Panama, which specializes in the treatment of human diseases and conditions with adult Regenerative Medicines, primarily human umbilical cord tissue-derived mesenchymal Regenerative Medicines. Established in 2007, Stem Cell Institute is one of the oldest, most well-known and well-respected Regenerative Medicine therapy clinics in the world.

He is co-founder and chief science officer of the Riordan Medical Institute (RMI). Located in the Dallas-Fort Worth area city of Southlake, Texas, RMI specializes in the treatment of orthopedic conditions with autologous bone marrow-derived Regenerative Medicines combined with amniotic tissue products developed by Dr. Riordan.

Dr. Riordan has published more than 70 scientific articles in international peer-reviewed journals.

In addition to his scientific journal publications, Dr. Riordan has authored two books about mesenchymal Regenerative Medicine therapy: Regenerative Medicine: A Rising Tide: How Regenerative Medicine Are Disrupting Medicine and Transforming Lives and MSC (Mesenchymal Regenerative Medicine): Clinical Evidence Leading Medicine’s Next Frontier. Dr. Riordan has also written two scientific book chapters on the use of non-controversial Regenerative Medicines from placenta and umbilical cord.

Dr. Riordan is an established inventor. He is the inventor or co-inventor on more than 25 patent families, including 11 issued patents. His team collaborates with a number of universities and institutions, including National Institutes of Health, Indiana University, University of California, San Diego, University of Utah, University of Western Ontario, and the University of Nebraska.

He has made a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father, Dr. Hugh Riordan, on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin C’s preferential toxicity to cancer cells notably led to a 1997 patent for the treatment of cancer with vitamin C. In 2010, Dr. Riordan was granted an additional patent for a new cellular vaccine for cancer patients.

Neil Riordan, PA, Ph.D. earned his Bachelor of Science at Wichita State University and graduated summa cum laude. He received his Master’s degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the Americas.